El valor de la selección de pacientes en NSCLC: tratamiento de segunda línea en pacientes PD-L1 positivo - page 23

Nivo
Doc
Nivo
Doc
100
90
80
70
60
50
40
30
10
0
20
Time (months)
100
90
80
70
60
50
40
30
10
0
20
24
21
18
15
12
9
6
3
0
27
Time (months)
24
21
18
15
12
9
6
3
0
27
Symbols represent censored observations.
OS by PD-L1 Expression
mOS
(mo)
Nivo
10.4
Doc
10.1
mOS (mo)
Nivo
17.2
Doc
9.0
mOS
(mo)
Nivo
9.9
Doc
10.3
mOS (mo)
Nivo
19.4
Doc
8.0
Time (months)
≥5% PD-L1 expression level
<5% PD-L1 expression level
mOS (mo)
Nivo
18.2
Doc
8.1
mOS
(mo)
Niv
o
9.7
Doc
10.1
≥1% PD-L1 expression level
HR (95% CI) = 0.59 (0.43, 0.82)
Time (months)
<1% PD-L1 expression level
OS (%)
HR (95% CI) = 0.90 (0.66, 1.24)
HR (95% CI) = 0.43 (0.30, 0.63)
HR (95% CI) = 1.01 (0.77, 1.34)
OS (%)
Time (months)
Time (months)
≥10% PD-L1 expression level
<10% PD-L1 expression level
HR (95% CI) = 0.40 (0.26, 0.59)
HR (95% CI) = 1.00 (0.76, 1.31)
24
21
18
15
12
9
6
3
0
27
100
90
80
70
60
50
40
30
10
0
20
100
90
80
70
60
50
40
30
10
0
20
24
21
18
15
12
9
6
3
0
27
24
21
18
15
12
9
6
3
0
27
100
90
80
70
60
50
40
30
10
0
20
24
21
18
15
12
9
6
3
0
27
100
90
80
70
60
50
40
30
10
0
20
1...,13,14,15,16,17,18,19,20,21,22 24,25,26,27,28,29,30,31,32,33,...43
Powered by FlippingBook